Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

By K. Olivier, D. Weber, Richard J. Wallace, A. Faiz, J. Lee, Yansheng Zhang, Barbara A Brown-Elliot, A. Handler, R. Wilson, M. Schechter and 3 more. American Journal of Respiratory and Critical Care Medicine, 2003

647 citations recorded by the source corpus.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/56e0156bcdbb34fa553c913b246154d0cdecae1d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. D. R. Prevots
2. T. Marras
3. B. Brown-Elliott
4. Richard J. Wallace

In Surgery

1. John W. Wilson

Citations in the corpus

• Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications (2010, background): “Since the incidence of nontuberculous mycobacterial (NTM) pulmonary infections is also increasing among CF patients, it is feared that azithromycin therapy may induce selection or acquisition of macrolide resistance in NTM (167, 215).”
• Pathophysiology and management of pulmonary infections in cystic fibrosis. (2003, background): “Treatment guidelines for the management of nontuberculous mycobacteria are evolving as more information becomes available on the epidemiology and clinical course of patients with CF culturing these organisms (165, 166).”
• A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae (2009, background): “abscessus is being recognized as an emerging pathogen following trauma and surgery and in patients with cystic fibrosis (15, 35, 36).”
• The Changing Microbial Epidemiology in Cystic Fibrosis (2010, background): “A multicenter study by Olivier and colleagues (226), in which M.”
• Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. (2003, background): “In a multicenter study conducted in 1000 patients with CF aged 10 years or older, the prevalence of nontuberculous mycobacteria was approximately 12%,althoughmanypatientsdidnot fulfillAmericanThoracicSocietycriteria for active disease.(33,34) Because of these concerns, potential participants in the ”
• Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. (2012, result): “The higher prevalence of disease among older adults living in southeastern and western states is consistent with prior reports of higher human exposure and observed prevalence (5, 37, 38) and with studies isolating greater numbers of mycobacteria from southeastern states than from other locations su”
• Epidemiology of Human Pulmonary Infection with Non-Tuberculous Mycobacteria: A Review (2014, background): “Persons with cystic fibrosis are disproportionately affected by NTM, with a national prevalence estimated at 13% (21), and this topic will be covered in a separate chapter.”